Vinva Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $638K | Buy |
5,085
+336
| +7% | +$42.1K | 0.02% | 339 |
|
|
2025
Q1 | $537K | Sell |
4,749
-8,542
| -64% | -$967K | 0.02% | 324 |
|
|
2024
Q4 | $1.82M | Sell |
13,291
-25,249
| -66% | -$3.46M | 0.07% | 236 |
|
|
2024
Q3 | $4.43M | Buy |
38,540
+21,795
| +130% | +$2.51M | 0.19% | 126 |
|
|
2024
Q2 | $2.25M | Buy |
16,745
+10,266
| +158% | +$1.38M | 0.11% | 191 |
|
|
2024
Q1 | $894K | Buy |
6,479
+1,678
| +35% | +$231K | 0.05% | 299 |
|
|
2023
Q4 | $634K | Buy |
4,801
+650
| +16% | +$85.9K | 0.04% | 311 |
|
|
2023
Q3 | $478K | Sell |
4,151
-1,063
| -20% | -$122K | 0.04% | 299 |
|
|
2023
Q2 | $493K | Sell |
5,214
-9,215
| -64% | -$871K | 0.04% | 306 |
|
|
2023
Q1 | $1.43M | Buy |
+14,429
| New | +$1.43M | 0.12% | 196 |
|